IPM Take
Neurology has spent decades treating the consequences of nerve damage after it has happened. Weakness. Pain. Numbness. Lost movement. Lost independence.
SARM1 changes the ambition. The target sits inside a pathway that helps trigger axon degeneration itself. Blocking it may not cure every neurological disease, but it could create a different kind of medicine: one that protects the wiring before the function disappears.
That idea is powerful. It is also early. The risk now is not scientific caution. The risk is pretending that a compelling mechanism is already a patient benefit.
Executive Summary
Recent coverage in Chemical & Engineering News and a June 2026 expert discussion at the Peripheral Nerve Society meeting highlight the clinical emergence of SARM1 inhibition, a strategy intended to interrupt programmed axon degeneration. SARM1 is an enzyme involved in the active breakdown of injured or stressed axons.
SARM1-targeted programmes are now in or approaching clinical development, including work in amyotrophic lateral sclerosis and peripheral neuropathy. The scientific rationale is strong, but the clinical questions remain substantial: which patients have active SARM1-driven biology, which biomarkers can identify them, how durable protection may be, and whether preserving axons will translate into meaningful functional benefit.
Why it matters
- Patients / advocates: Protecting axons could matter across conditions where function is lost slowly and then becomes difficult to recover.
- Researchers / academia: Human biomarkers and patient selection will decide whether a promising pathway becomes a useful treatment.
- Industry and regulators: Programmes must prove more than target engagement. They must show preserved function, not only preserved nerve tissue.
The most important part of a nerve may be the part medicine usually sees too late.
By the time weakness, numbness, pain or paralysis becomes obvious, an axon may already be damaged beyond repair. Much of neurology is built around this reality: manage symptoms, suppress upstream disease, rehabilitate what can be saved.
SARM1 inhibitors are attempting something more fundamental.
SARM1 is part of a cellular pathway that actively dismantles injured or stressed axons. In laboratory models, blocking the pathway can preserve axons that would otherwise degenerate. That has made SARM1 one of the more compelling emerging targets across ALS, inherited neuropathies and treatment-related peripheral nerve damage.
But biology alone is not a treatment.
The hard part is translating a common pathway across very different diseases. ALS is heterogeneous. Peripheral neuropathy has many causes. In some patients, SARM1 may be central to ongoing axon loss. In others, it may be a downstream feature of damage that has already become irreversible.
That is why biomarkers are not a side issue. They are the access issue.
A future SARM1 inhibitor may work best not for everyone with a diagnostic label, but for people whose disease shows evidence of active axonal degeneration at the right stage, in the right tissue, at the right time.
This is precision neurology at its most demanding. Not a broad promise to “protect nerves”, but a test of whether medicine can identify who still has something to save.
